Lyon, France, June 21, 2018<\/strong> – MaaT Pharma, a clinical-stage microbiome therapy company, and SATT Lutech, a private technology transfer company holding the exclusive rights to the scientific findings from research groups at Sorbonne University, APHP, CNRS and INSERM, today announced a licensing agreement under which MaaT Pharma will receive world-wide exclusive rights for the therapeutic application of allogeneic Fecal Microbiome Transplants (FMT) to treat acute Graft-vs-Host Disease (GvHD) in patients following stem cell transplantation. The technology is based on research performed within the Clinical Hematology Department at Saint-Antoine Hospital and Sorbonne University, Paris, France. The license builds the foundation for MaaT Pharma\u2019s MaaT013 program for which the company recently received authorization from the French regulatory authorities to launch a multicenter Phase 2 study in acute GvHD. GvHD is a major complication of allogeneic hematopoietic stem cell transplantation in which the donor\u2019s immune effector cells attack the recipient\u2019s tissue, causing inflammation, severe damage and often death.MaaT Pharma has developed a unique cGMP platform for next generation FMTs that are based on allogeneic donor material and tailored to disease treatment needs through a thorough analytical screening and reproducible production process. In parallel, the company is developing FMT drugs to prolong survival in acute myeloid leukemia patients by reintroducing a functional microbiome after chemotherapy. A Phase 1\/2 study launched in 2016 is being concluded and results to establish proof-of-concept are expected over this summer.<\/p>\n Founded at the end of 2014, MaaT Pharma (Microbiota as a Therapy) is a clinical-stage biotech company revolutionizing and shaping a new approach to therapies in order to treat serious diseases linked to gut microbiota imbalances. With its breakthrough proprietary platforms (GMP Fecal Microbiome Transfer platform and g\u039bt Print, its proprietary data science platform), MaaT Pharma is creating FMT-based products and solutions for patients suffering from severe diseases. Addressing currently unmet clinical needs, MaaT Pharma\u2019s revolutionary and rapid approach plays a considerable part in the evolution of treatment therapies. In the upcoming years, with the on-going support from strategic partners and investors, MaaT Pharma will develop patient-friendly solutions (oral forms) to improve overall survival, reduce infectious episodes, reduce gastrointestinal complications and hinder multidrug-resistant bacteria onset. MaaT Pharma receives world-wide exclusive license to technology co-developed with hematology and gastroenterology departments of Saint-Antoine Hospital, Paris.<\/p>\n","protected":false},"author":2,"featured_media":4533,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[52],"class_list":["post-4530","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-fr","year_press-52"],"acf":[],"yoast_head":"\nAbout MaaT Pharma<\/em><\/h3>\n
\nFor additional information, please visit www.maatpharma.com<\/a> and follow us on Twitter @MaaT_Pharma<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"